Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(3-fluoro-4-(((3-(2-methyl-2-propanyl)-1-(6-quinolinyl)-1h-pyrazol-5-yl)carbamoyl)amino)phenoxy)-n-methyl-2-pyridinecarboxamide
1. 1020172-07-9
2. Dcc-2036
3. Dcc-2036 (rebastinib)
4. Dcc 2036
5. Dcc2036
6. Rebastinib [usan]
7. 4-(4-(3-(3-(tert-butyl)-1-(quinolin-6-yl)-1h-pyrazol-5-yl)ureido)-3-fluorophenoxy)-n-methylpicolinamide
8. Chebi:62166
9. Dp-1919
10. Dcc-2036 Free Base
11. Rebastinib (usan)
12. 4-[4-({[3-tert-butyl-1-(quinolin-6-yl)-1h-pyrazol-5-yl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
13. 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
14. N-[3-tert-butyl-1-(quinolin-6-yl)-1h-pyrazol-5-yl]-n'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea
15. 75017q6i97
16. 1-[3-tert-butyl-1-(quinolin-6-yl)-1h-pyrazol-5-yl]-3-{2-fluoro-4-[2-(methylcarbamoyl)pyridin-4-yloxy]phenyl}urea
17. 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide,4-methylbenzenesulfonic Acid;4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide,4-methylbenzenesulfonic Acid
18. Rebastinib [usan:inn]
19. 3qri
20. 3qrj
21. Unii-75017q6i97
22. 2-pyridinecarboxamide, 4-(4-((((3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1h-pyrazol-5-yl)amino)carbonyl)amino)-3-fluorophenoxy)-n-methyl-
23. 2-pyridinecarboxamide, 4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1h-pyrazol-5-yl]amino]carbonyl]amino]-3-fluorophenoxy]-n-methyl-
24. Dp 1919
25. Rebastinib [inn]
26. Dcc-2036; Rebastinib
27. Rebastinib(dcc-2036)
28. Rebastinib [who-dd]
29. Mls006011270
30. Gtpl9173
31. Schembl2034290
32. Chembl1738757
33. Dtxsid40144533
34. Bdbm185674
35. Hms3656h07
36. Hms3672i07
37. Amy39865
38. Bcp02345
39. Ex-a2046
40. Mfcd19443646
41. Nsc774831
42. Nsc800863
43. S2634
44. Zinc63933734
45. Akos025404839
46. Bcp9000591
47. Ccg-264972
48. Cs-1038
49. Db13005
50. Nsc-774831
51. Nsc-800863
52. Sb16618
53. Ncgc00263172-01
54. Ncgc00263172-09
55. 4-(4-(3-(3-tert-butyl-1-(quinolin-6-yl)-1h-pyrazol-5-yl)ureido)-3-fluorophenoxy)-n-methylpicolinamide
56. Ac-30301
57. As-17048
58. Da-34916
59. Hy-13024
60. Smr004703020
61. Ft-0760974
62. Sw219251-1
63. J3.653.310b
64. D10334
65. Q27088522
66. 4-(3-fluoro-4-(((3-(2-methyl-2-propanyl)-1-(6-quinolinyl)-1h-pyrazol-5-yl)carbamoyl)amino)phenoxy)-n-methyl-2-pyridinecarboxamide
67. 4-(4-(((3-tert-butyl-1-(quinolin-6-yl)-1h-pyrazol-5-yl)carbamoyl(amino)-3-fluorophenoxy)-n-methylpyridin-2-carboxamide
68. N-(3-(1,1-dimethylethyl)-1-(quinolin-6-yl)-1h-pyrazol-5-yl)-n'-(2-fluoro-4-((2- (methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea
Molecular Weight | 553.6 g/mol |
---|---|
Molecular Formula | C30H28FN7O3 |
XLogP3 | 4.9 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | 553.22376594 g/mol |
Monoisotopic Mass | 553.22376594 g/mol |
Topological Polar Surface Area | 123 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 904 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
ABOUT THIS PAGE
64
PharmaCompass offers a list of Rebastinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rebastinib manufacturer or Rebastinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rebastinib manufacturer or Rebastinib supplier.
PharmaCompass also assists you with knowing the Rebastinib API Price utilized in the formulation of products. Rebastinib API Price is not always fixed or binding as the Rebastinib Price is obtained through a variety of data sources. The Rebastinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rebastinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rebastinib, including repackagers and relabelers. The FDA regulates Rebastinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rebastinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rebastinib supplier is an individual or a company that provides Rebastinib active pharmaceutical ingredient (API) or Rebastinib finished formulations upon request. The Rebastinib suppliers may include Rebastinib API manufacturers, exporters, distributors and traders.
Rebastinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rebastinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rebastinib GMP manufacturer or Rebastinib GMP API supplier for your needs.
A Rebastinib CoA (Certificate of Analysis) is a formal document that attests to Rebastinib's compliance with Rebastinib specifications and serves as a tool for batch-level quality control.
Rebastinib CoA mostly includes findings from lab analyses of a specific batch. For each Rebastinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rebastinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Rebastinib EP), Rebastinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rebastinib USP).